title: Viral hepatitis and liver transplantation.
abstract: Hepatitis C is the one of the most common indications for liver transplantation. Infection of the allograft after transplantation is universal, and recurrent hepatitis C progresses at an accelerated rate. Antiviral therapy in selected patients on the transplant waiting list may reduce the rate of hepatitis C virus reinfection. Preemptive antiviral therapy after transplantation has been disappointing. However, treatment of established histological disease with a combination of pegylated interferon and ribavirin is associated with sustained virologic response rates of 25 to 40%. Significant advances have been made in the prevention of hepatitis B reinfection after transplantation. Results are now excellent, with graft infection rates less than 10%. The challenges for the future include designing strategies to optimize the use of antiviral agents to prevent the need for transplantation and to avoid antiviral resistance and to determine the dose and duration of hepatitis B immunoglobulin needed in the era of multiple nucleoside analogs.
authors.affiliation: Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan 48109-0362, USA.
authors.forename: Pratima
authors.initials: P
authors.lastname: Sharma
authors.forename: Anna
authors.initials: A
authors.lastname: Lok
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D006085:Graft Survival; D006509:Hepatitis B / Q000628:therapy*; D017325:Hepatitis B Vaccines; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D007165:Immunosuppression Therapy / Q000009:adverse effects; D016031:Liver Transplantation; D019520:Living Donors; D011182:Postoperative Care; D011300:Preoperative Care; D012086:Reoperation; D055502:Secondary Prevention
chemical_list: D000998:Antiviral Agents; D017325:Hepatitis B Vaccines; D007136:Immunoglobulins